""Beyond supply and affordability, one of the bigger barriers to adoption has been that some patients just don't want to take an injection. That could be because it's a needle, but it also may just be that for them, an injection signifies that their condition is more severe than they feel it is at that point.""
""Pills are also easier to manufacture than injectable medications, which could help maintain continual access for patients. GLP-1 medications were in severe shortage from late 2022 through early 2025 because demand outstripped manufacturing capacity.""
Foundayo, a new obesity pill approved by the FDA, is manufactured by Eli Lilly and is a GLP-1 medication. It can be taken at any time without food restrictions, unlike the Wegovy pill. The demand for injectable GLP-1 drugs has led to a race among pharmaceutical companies to develop oral alternatives. Foundayo aims to address barriers to adoption, as some patients prefer pills over injections. The medication starts at a low dose to reduce side effects like nausea and diarrhea, similar to other GLP-1 drugs.
Read at WIRED
Unable to calculate read time
Collection
[
|
...
]